HK1207288A1 - Itraconazole compositions and dosage forms, and methods of using the same - Google Patents
Itraconazole compositions and dosage forms, and methods of using the same Download PDFInfo
- Publication number
- HK1207288A1 HK1207288A1 HK15107854.3A HK15107854A HK1207288A1 HK 1207288 A1 HK1207288 A1 HK 1207288A1 HK 15107854 A HK15107854 A HK 15107854A HK 1207288 A1 HK1207288 A1 HK 1207288A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- composition
- itraconazole
- oral pharmaceutical
- pharmaceutical composition
- auc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902624 | 2012-06-21 | ||
| AU2012902624A AU2012902624A0 (en) | 2012-06-21 | Itraconazole formulations and uses | |
| PCT/US2013/047135 WO2013192566A1 (en) | 2012-06-21 | 2013-06-21 | Itraconazole compositions and dosage forms, and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207288A1 true HK1207288A1 (en) | 2016-01-29 |
Family
ID=49769445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107854.3A HK1207288A1 (en) | 2012-06-21 | 2013-06-21 | Itraconazole compositions and dosage forms, and methods of using the same |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US8921374B2 (https=) |
| EP (1) | EP2863911A4 (https=) |
| JP (2) | JP2015531749A (https=) |
| KR (3) | KR20200065093A (https=) |
| CN (2) | CN104507480A (https=) |
| AU (3) | AU2013278001A1 (https=) |
| BR (1) | BR112014031706A8 (https=) |
| CA (1) | CA2876909C (https=) |
| HK (1) | HK1207288A1 (https=) |
| MX (1) | MX366829B (https=) |
| WO (1) | WO2013192566A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014031706A8 (pt) | 2012-06-21 | 2021-10-19 | Mayne Pharma Int Pty Ltd | Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| US11390613B2 (en) | 2017-08-20 | 2022-07-19 | University Of Connecticut | Azole analogues and methods of use thereof |
| AU2019277362A1 (en) * | 2018-05-30 | 2021-01-21 | Mayne Pharma International Pty Ltd | Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome |
| WO2021030174A1 (en) | 2019-08-09 | 2021-02-18 | University Of Connecticut | Truncated itraconazole analogues and methods of use thereof |
| CN115768779A (zh) * | 2020-05-07 | 2023-03-07 | 上海偕怡医药科技有限公司 | 伊曲康唑前药及其用途 |
| WO2023007514A1 (en) * | 2021-07-29 | 2023-02-02 | Dr. Reddy's Laboratories Limited | Improved oral bioavailable pharmaceutical compositions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3110794B2 (ja) | 1991-06-05 | 2000-11-20 | ユーシービージャパン株式会社 | １，４−ジヒドロピリジン誘導体を含有する製剤 |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| US6254889B1 (en) | 1995-07-26 | 2001-07-03 | Kyowa Hakko Kogyo Co., Ltd. | Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer |
| ATE255883T1 (de) | 1996-05-20 | 2003-12-15 | Janssen Pharmaceutica Nv | Fungizide mittel mit verbesserter bioverfügbarkeit |
| DE69730241T2 (de) | 1996-06-28 | 2005-08-11 | Schering Corp. | Feste lösung eines fungizids mit erhöhter bioverfügbarkeit |
| CA2317106C (en) | 1997-12-31 | 2004-11-23 | Choongwae Pharma Corporation | Method and composition of an oral preparation of itraconazole |
| KR100336090B1 (ko) | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
| JP2002534371A (ja) | 1999-01-06 | 2002-10-15 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物 |
| EP1027886B1 (en) | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
| EP2415462A1 (en) * | 1999-12-23 | 2012-02-08 | Mayne Pharma International Pty Ltd. | Improved pharmaceutical compositions for poorly soluble drugs |
| KR100425755B1 (ko) * | 2001-08-27 | 2004-04-03 | 주식회사 원진신약 | 이트라코나졸을 함유하는 조성물 및 그 제조방법 |
| KR100529766B1 (ko) * | 2003-09-09 | 2005-11-17 | 한미약품 주식회사 | 음식물 섭취에 따른 영향이 적은, 이트라코나졸경구투여용 조성물 및 이의 제조 방법 |
| US20050058670A1 (en) | 2003-09-09 | 2005-03-17 | Jong-Soo Woo | Oral itraconazole composition which is not affected by ingested food and process for preparing same |
| JP4342426B2 (ja) * | 2004-11-24 | 2009-10-14 | 科研製薬株式会社 | イトラコナゾール経口投与用製剤 |
| US8486456B2 (en) * | 2005-08-08 | 2013-07-16 | Abbott Gmbh & Co., Kg | Itraconazole compositions with improved bioavailability |
| WO2008002568A2 (en) * | 2006-06-26 | 2008-01-03 | Mutual Pharmaceutical Company, Inc. | Active agent formulations, methods of making, and methods of use |
| US20110262517A1 (en) * | 2007-04-05 | 2011-10-27 | The Johns Hopkins University | Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a-demethylase for use as angiogenesis inhibitors |
| BR112014031706A8 (pt) | 2012-06-21 | 2021-10-19 | Mayne Pharma Int Pty Ltd | Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol |
-
2013
- 2013-06-21 BR BR112014031706A patent/BR112014031706A8/pt active Search and Examination
- 2013-06-21 WO PCT/US2013/047135 patent/WO2013192566A1/en not_active Ceased
- 2013-06-21 CA CA2876909A patent/CA2876909C/en active Active
- 2013-06-21 AU AU2013278001A patent/AU2013278001A1/en not_active Abandoned
- 2013-06-21 KR KR1020207015341A patent/KR20200065093A/ko not_active Ceased
- 2013-06-21 CN CN201380040270.9A patent/CN104507480A/zh active Pending
- 2013-06-21 KR KR1020217010610A patent/KR20210043721A/ko not_active Abandoned
- 2013-06-21 MX MX2015000179A patent/MX366829B/es active IP Right Grant
- 2013-06-21 KR KR20157001531A patent/KR20150043296A/ko not_active Ceased
- 2013-06-21 CN CN201811419638.3A patent/CN109674795A/zh active Pending
- 2013-06-21 EP EP13806558.6A patent/EP2863911A4/en active Pending
- 2013-06-21 HK HK15107854.3A patent/HK1207288A1/xx unknown
- 2013-06-21 JP JP2015518624A patent/JP2015531749A/ja active Pending
- 2013-06-21 US US13/924,222 patent/US8921374B2/en active Active
-
2014
- 2014-10-10 US US14/511,420 patent/US9272046B2/en active Active
-
2015
- 2015-10-14 US US14/882,662 patent/US9713642B2/en active Active
-
2017
- 2017-06-15 US US15/623,742 patent/US20170348421A1/en not_active Abandoned
-
2018
- 2018-02-22 AU AU2018201298A patent/AU2018201298B2/en active Active
- 2018-07-02 JP JP2018126027A patent/JP6757367B2/ja active Active
- 2018-11-21 US US16/198,645 patent/US10463740B2/en active Active
-
2019
- 2019-11-01 US US16/671,606 patent/US10806792B2/en active Active
-
2020
- 2020-08-14 AU AU2020217438A patent/AU2020217438A1/en not_active Abandoned
- 2020-10-19 US US17/074,497 patent/US11638758B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11638758B2 (en) | Itraconazole compositions and dosage forms, and methods of using the same | |
| EP2950797B1 (en) | Compositions and methods for the treatment of neurodegenerative and other diseases | |
| BRPI0915284B1 (pt) | composição farmacêutica oral, e, uso de uma composição farmacêutica | |
| JP7190425B2 (ja) | 肝細胞癌の治療のための併用療法 | |
| AU2026202283A1 (en) | Treatment of prostate cancer with a combination of abiraterone acetate and niraparib | |
| CN113286587A (zh) | 用于治疗iv型胶原病的联苯磺酰胺化合物 | |
| JP2025522785A (ja) | 多発性硬化症及び重症筋無力症に対する治療用チロシンキナーゼ阻害剤 | |
| EP4301356A1 (en) | Treatment of breast cancer with amcenestrant and palbociclib | |
| EP3993809B1 (en) | System for enhancing therapeutic compliance of the anti-cancer compound e7766 | |
| WO2024081948A1 (en) | Combination for use in treating cancers | |
| CN119546312A (zh) | 用于治疗银屑病的包含a3腺苷受体激动剂的药物组合物 | |
| TWI914354B (zh) | 用於治療癌症之VCP/p97抑制劑 | |
| WO2023007514A1 (en) | Improved oral bioavailable pharmaceutical compositions | |
| US20230241028A1 (en) | Treatment of ovarian cancer with nirogacestat | |
| TW202207938A (zh) | 用於治療癌症之VCP/p97抑制劑 |